

Neuromuscular Biology and Disease, Spring semester 2014.
Duchenne muscular dystrophy.

Course organizers: Denis Guttridge and Jill Rafael-Fortney

Topic: Interactions between dystrophic muscle and the immune system.


Jim Tidball

Program in Molecular, Cellular and Integrative Physiology

Department of Pathology and Laboratory Medicine

UCLA

Mechanical signal transduction in muscle.



Mechanical defect hypothesis


Mutation of dystrophin

Loss of normal dystrophin expression

Mechanical weakening of cell membrane

Membrane lysis

Cell death



Dystrophin-deficient DMD humans

Clinical onset

(3 to 4 years of age)



Muscle fiber injury

Progressive pathology

(continuous, following initial onset)



Failed regeneration; fibrosis; death by third decade

Dystrophin-deficient *mdx* mice

Acute onset stage

(3 to 4 weeks of age)



Muscle fiber injury

Regenerative stage

(6 to 12 weeks of age)




Successful regeneration

Progressive stage

(1 year and older)



Failed regeneration; fibrosis;
death by two years



Duchenne muscular dystrophy.


Jorde et al. (2000) Medical Genetics.

Healthy muscle.

Goals for presentation:


- learn the major populations of immune cells present in dystrophic muscle;
- learn interactions between immune cells and dystrophic muscle;
- learn mechanisms that influence inflammatory cell phenotype;
- learn relationships between inflammatory cell phenotype and stages of muscular dystrophy.

Hematopoietic stem cells are the source of multiple cell lineages that have the potential to affect growth, regeneration and function of other tissues.



<http://stemcell.nih.gov.info>

HSCs are the source of multiple cell lineages that can affect growth, regeneration and function of other tissues.




Innate immunity:


- relatively rapid
- non-specific;
- inflammation
- humoral immunity
- (complement system)
- cellular immunity
- (mostly myeloid cells)

Acquired immunity:

- develops over time
- pathogen specific
- immunological memory
- humoral immunity
- (antibodies);
- cellular immunity
- (mostly lymphocyte mediated)




Macrophages in 4 wk *mdx* muscle



Macrophages:


- differentiate from monocytes;
- phagocytic;
- can lyse other cells via free radicals;
- release soluble factors that can regulate the functions of myeloid cells and lymphoid cells;
- can present antigen to lymphocytes to influence their activation.
- release factors that can influence growth and differentiation of multiple cell types.





Macrophages isolated from 4 wk old *mdx* muscles are highly cytolytic.

(Wehling et al. (2001) J. Cell Biol.)

Image by Dr. James Evans, MIT




Macrophages in 4-wk-old *mdx* muscles are highly cytolytic.



In vivo depletions of macrophages in *mdx* mice reduces muscle membrane lysis by more than 70%.

(Wehling et al. (2001) J. Cell Biol.)

Phenotypically-distinct macrophages are co-distributed in *mdx* muscle lesions




Villalta et al. (2009)
Human Molecular Genetics

Phenotyping cell populations by flow cytometry

Assay single sample for cells expressing two or more markers

■ Marker 1


■ Marker 2



Assay two samples for expression of a single marker.

■ Sample 1

■ Sample 2



Time course of muscle pathology and macrophage phenotype switching in muscular dystrophy.

Acute onset stage

(3 to 4 wks of age)



Muscle fiber injury

Regenerative stage

(6 to 12 wks of age)



Successful regeneration

Progressive stage

(1 year and older)



Failed regeneration; fibrosis

M1 macrophages

F4/80⁺/CD163⁻/CD206⁻

cytolytic

pro-inflammatory

iNOS^{high}

arginase^{low}

M2c macrophages

F4/80⁺/CD163⁺/CD206⁺

non-cytolytic

anti-inflammatory

iNOS^{low}

arginase^{low}

M2a macrophages

F4/80⁺/CD163⁺/CD206⁺

non-cytolytic


anti-inflammatory

iNOS^{low}


arginase^{high}

Helper T-cells (T_h cells):

- differentiate in thymus;
- rich source of cytokines that influence the activities of other immune cells;
- learn to recognize and bind specific antigenic peptides that affect T-cell function and proliferation;
- can differentiate into:
 - effector T-cells (Th1 or Th2),
 - memory T-cells,
 - regulatory T-cells.




Cytokine modulation of immune cell functions.



Fates of M1 and M2 macrophages.

M1 macrophages


(classical activation)



Acute peak of pathology

M2 macrophages

(alternative activation)




Regenerative and progressive stages


Pro-inflammatory pathways in *mdx* macrophages

iNOS:


- (inducible nitric oxide synthase);
- transcriptionally regulated by proinflammatory cytokines;
- rapidly generates high concentrations of nitric oxide (NO);
- can lyse target and bystander cells.




Ablating iNOS expression reduces the pathology of *mdx* dystrophy.



Macrophage lysis of muscle cells in vitro (% total)



Number of muscle fibers




(Villalta et al. (2009) Human Molec. Genetics)


Pro-inflammatory pathways in *mdx* macrophages

IFN γ :




- interferon-gamma;
- potent Th1 cytokine;
- strong inducer of M1 phenotype;
- activates iNOS transcription.



Ablating IFN γ -mediated signaling reduces the pathology of *mdx* dystrophy.



Injured fibers marked with fluorescent tracer.




(Villalta et al. (2011) J. Immunol.)

What regulates macrophage phenotype switch in dystrophic muscle?

M1 macrophages


(classical activation)



Acute peak of pathology

M2 macrophages


(alternative activation)




Regenerative and progressive stages

Tregs:

- regulatory T-cells
- can suppress immune responses
- prevent pathological self-reactivity
- CD4+ / FoxP3+ / CD25+
- can inhibit interferon- γ (IFN γ) secretion
- can increase IL-10 and IL-6 secretion.




Treg depletion before acute muscle injury shifts macrophages toward an M1 phenotype.



Can Tregs regulate the immune response in muscular dystrophy?


- about one-third of the T-cells in *mdx* muscle are Tregs.



(Burzyn et al. (2013) Cell)

Can Tregs regulate the immune response in muscular dystrophy?



- Treg depletion worsens damage of dystrophic muscle.



(Burzyn et al. (2013) Cell)


Can Tregs regulate the immune response in muscular dystrophy?

- Treg depletion worsens damage of dystrophic muscle.




(Burzyn et al. (2013) Cell)


Time course of muscle pathology and macrophage phenotype switching in muscular dystrophy.



Time course of muscle pathology and macrophage phenotype switching in muscular dystrophy.




Arginine metabolism by macrophages



Villalta et al., 2009. Human Molecular Genetics.
Wehling-Henricks et al. 2010. PLoS One.

Quadriceps of 24 month old mice.




C57


mdx

Tidball and Wehling-Henricks. Pediatric Res. (2004)

Kyphoscoliosis is a prominent feature of DMD and *mdx* pathologies.



Dystrophin-deficient hearts display fibrotic lesions.




Wild-type


Dystrophin-deficient

Wehling-Henricks et al. Human Molec. Genetics (2005)

Arginine metabolism by M2 macrophages increases fibrosis of dystrophin-deficient muscles and hearts.




■ wild-type
 □ arginase k/o
 ■ *mdx*
 ■ arginase ko / *mdx*




■ C57 D-arginine
 □ C57 L-arginine
 ■ *mdx* D-arginine
 ■ *mdx* L-arginine

Arginine metabolism by M2 macrophages increases fibrosis of dystrophin-deficient muscles and hearts.



■ wild-type
 □ arginase k/o
 ■ *mdx*
 ■ arginase ko / *mdx*



■ C57 D-arginine
 □ C57 L-arginine
 ■ *mdx* D-arginine
 ■ *mdx* L-arginine

(400 mg Arg / kg body mass / day)

Conclusions:

Muscle fiber injury

Successful regeneration

Failed regeneration; fibrosis

M1 macrophages

M2c macrophages

M2a macrophages

- the immune system plays a significant role in regulating the pathology of muscular dystrophy;
- specific subpopulations of macrophages serve distinct and potentially competitive functions in muscular dystrophy;
- manipulation of macrophage activation, numbers or phenotype can affect the course of muscle disease;
- short-term gains achieved by therapeutic interventions into muscle disease may lead to unpredictable and detrimental long-term effects.

Dystrophin-deficient DMD humans

Clinical onset

(3 to 4 years of age)

Progressive pathology

(continuous, following initial onset)

Muscle fiber injury

Failed regeneration; fibrosis; death by third decade

Can manipulation of the immune response to DMD improve the regenerative capacity of muscular dystrophy patients?

Muscle fiber injury

Successful regeneration

Failed regeneration; fibrosis;
death by two years

Acute onset stage

Regenerative stage

Progressive stage

(3 to 4 weeks of age)

(6 to 12 weeks of age)

(1 year and older)

Dystrophin-deficient *mdx* mice